Company Filing History:
Years Active: 2013
Title: Tanja Rothammer-Hampl: Innovator in Chemotherapeutic Advancements
Introduction
Tanja Rothammer-Hampl is a notable inventor based in Haibach, Germany. She has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative treatments for cancer. Her work focuses on combining chemotherapeutic agents with inhibitors of the TGF-beta system, showcasing her commitment to advancing medical science.
Latest Patents
Tanja Rothammer-Hampl holds one patent that is particularly noteworthy. The patent is titled "Combination of a chemotherapeutic agent and an inhibitor of the TGF-beta system." This pharmaceutical composition includes a chemotherapeutic agent and a TGF-beta antisense oligonucleotide. The antisense oligonucleotide is designed to reduce the sensitivity and IC of the cytotoxicity of the chemotherapeutic agent. The preferred chemotherapeutic agents mentioned in her patent include gemcitabine, 5-fluorouracil, temozolomide, dacarbacine, docetaxel, cisplatin, oxaliplatin, tamoxifen, and irinotecan.
Career Highlights
Tanja Rothammer-Hampl is associated with Antisense Pharma GmbH, where she continues to work on groundbreaking pharmaceutical innovations. Her research has the potential to improve treatment outcomes for cancer patients by enhancing the efficacy of existing chemotherapeutic agents.
Collaborations
Tanja collaborates with esteemed colleagues in her field, including Karl-Hermann Schlingensiepen and Frank Jaschinski. These collaborations contribute to the advancement of her research and the development of new therapeutic strategies.
Conclusion
Tanja Rothammer-Hampl is a pioneering inventor whose work in the pharmaceutical industry is making a significant impact on cancer treatment. Her innovative approach to combining chemotherapeutic agents with TGF-beta inhibitors exemplifies her dedication to improving patient care.